The dengue vaccine will be a single dose and is expected to arrive in Ecuador. The pharmaceutical company MSD assures that the effectiveness is 80%.
The continuous increase in dengue cases in Latin America is one of the factors why the Butantan Institute of Brazil and the pharmaceutical company MDS are working on creation of a vaccine against this disease.
The medical director of MSD, Fabiane El Far Sztajnbok, told PRIMICIAS that in July 2024 the results of the test will be ready last phase of research, with the objective of receiving authorization from the Brazilian government to apply it to the population.
Art, laughter and love for dogs at the Victoria Theater in Quito
“We have done tests on around 17,000 people from several countries in the region and results are good“, he assured during the 20th Latin American Seminar on Journalism in Science and Health, which is taking place in Brazil.
The Far Sztajnbok added that this vaccine “will be more than 80% effective“It will be a single dose for life and children from two years of age can receive it.”
Furthermore, he assured that the MSD’s objective is for the vaccine to reach Ecuador and to the other countries in the region affected by dengue.
According to the latest data from the Ministry of Health, until April 16, 2023, 6,094 cases of dengue that have left four dead.
2023-09-19 21:02:27
#vaccine #dengue #ready
